Table 4.
Generic names of beta-blockers and inhibitors of renin-angiotensin system that prescribed at discharge in propensity-score matched patients.
| Generic name | No. of patients | Mean dose (mg) | Median dose (mg) |
|---|---|---|---|
| Beta-blockers (N = 685) | |||
| Carvedilol | 344 (50) | 6.0 ± 6.0 | 3.125 (3.125, 6.25) |
| Bisoprolol | 291 (43) | 2.0 ± 1.5 | 1.25 (1.25, 2.5) |
| Nebivolol | 34 (5) | 3.0 ± 1.8 | 2.5 (1.25, 5.0) |
| Metoprolol | 9 (1) | 63.9 ± 28.3 | 50 (50, 100) |
| Others | 7 (1) | ||
| Angiotensin-converting enzyme inhibitors (N = 659)* | |||
| Perindopril | 329 (50) | 2.9 ± 1.3 | 2 (2, 4) |
| Ramipril | 264 (40) | 2.5 ± 1.4 | 2.5 (1.25, 2.5) |
| Captopril | 42 (6) | 24.5 ± 26.9 | 15.6 (9.4, 37.5) |
| Others | 24 (4) | ||
| Angiotensin receptor blockers (N = 353)* | |||
| Candesartan | 122 (35) | 6.8 ± 3.2 | 8 (4, 8) |
| Losartan | 86 (24) | 40.6 ± 16.9 | 50 (25, 50) |
| Telmisartan | 69 (20) | 43.1 ± 19.7 | 40 (40, 40) |
| Valsartan | 50 (14) | 80.4 ± 64.3 | 40 (40, 100) |
| Others | 26 (7) | ||
Values are number (%), mean ± standard deviation, or median (interquartile range).
*
Nine patients with both angiotensin-converting enzyme inhibitors and angiotensin receptor blockers.